Government-Owned Inventions; Availability for Licensing, 4603-4605 [E8-1244]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 17 / Friday, January 25, 2008 / Notices
jlentini on PROD1PC65 with NOTICES
completer protection according to the
immunogenicity data.
Application: Immunization against
Salmonella typhi for long term
prevention of typhoid fever in all ages.
Developmental Status: Conjugates
have been synthesized and clinical
studies have been performed. The
synthesis of the conjugates is described
by Kossaczka, et al. in Infect Immun.
1997 June;65(7):2088–2093. Phase III
clinical studies are described by Mai, et
al. in N Engl J Med. 2003 October 2;
349(14):1390–1391. Dosage studies are
described by Canh, et al. in Infect
Immun. 2004 Nov; 72(11):6586–6588.
A safety and immunogenicity study in
infants are under way. The aim is to
administer the conjugate vaccine with
routine infant immunization.
Preliminary results shows the vaccine is
safe in 2 months old infants.
Inventors: Zuzana Kossaczka,
Shousun C. Szu, and John B. Robbins
(NICHD).
Patent Status: U.S. Patent 6,797,275
issued 28 Sep 2004 (HHS Reference No.
E–020–1999/0–US–02); U.S. Patent
Application No. 10/866,343 filed 10 Jun
2004 (HHS Reference No. E–020–1999/
0–US–03); U.S. Patent Application No.
11/726,304 filed 20 Mar 2007 (HHS
Reference No. E–020–1999/0–US–04).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Child Health
and Human Development, Laboratory of
Developmental and Molecular
Immunity, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize A Method of Immunizing
Humans Against Salmonella Typhi
Using a Vi-rEPA Conjugate Vaccine.
Please contact John D. Hewes, Ph.D., at
301–435–3121 or hewesj@mail.nih.gov
for more information.
Dated: January 10, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–1232 Filed 1–24–08; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
16:59 Jan 24, 2008
Jkt 214001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone:
301/496–7057; fax: 301/402–0220. A
signed Confidential Disclosure
Agreement will be required to receive
copies of the patent applications.
Diagnosis and Treatment of Barrett’s
Esophagus and Associated Esophageal
Adenocarcinoma
Description of Invention: Barrett’s
esophagus is a condition in which the
normal esophageal tissue lining has
been replaced by an abnormal lining of
gastric and intestinal tissue resulting
from chronic gastroesophageal reflux
disease. Patients have an increased risk
of developing esophageal
adenocarcinoma, which is often
detected at later stages and is associated
with poor prognosis. Survival rates are
very low ranging from 10% in Europe to
16% in the United States.
Available for licensing are microRNA
(miRNA) biomarkers that show
differential expression in the
adenocarcinoma diagnosis and Barrett’s
esophagus status, and they can predict
diagnosis and Barrett’s esophagus with
accuracies of 71.4% and 74.7%,
respectively. Thus, these miRNA
biomarkers that may predispose
individuals to Barrett’s esophagus and/
or esophageal adenocarcinoma could
provide a means for earlier detection
and help in better identifying treatment
options.
Applications:
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
4603
Method to diagnose and treat Barrett’s
esophagus and esophageal
adenocarcinoma.
miRNA pharmaceutical compositions
to treat Barrett’s esophagus.
Advantages: Early diagnostic that can
more accurately stratify patients for
increased survival rates and appropriate
treatments.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Market: Esophageal cancer is the 8th
most common cancer and 6th most
common cause of cancer worldwide.
Survival rate of esophageal cancer is
10% to 16% in Europe and United
States respectively.
miRNA technologies have an
emerging market, and in 2007, it was
worth an estimated 23 million dollars in
the U.S. and it has a projected annual
growth rate of 100%.
Inventors: Ewy Mathe (NCI), Curtis C.
Harris (NCI), et al.
Patent Status: U.S. Provisional
Application No. 60/979,300 filed 11 Oct
2007 (HHS Reference No. E–008–2008/
0–US–01).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The Laboratory of Human
Carcinogenesis at the National Cancer
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize methods to diagnose and
treat Barrett’s esophagus and esophageal
carcinoma. Please contact John D.
Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Mouse Model for Obesity and Type 2
Diabetes Due to Inactivation of
ANKRD26 Gene
Description of Invention: Obesity and
type II diabetes are major health hazards
both in the United States and
internationally. The incidence of obesity
has been steadily increasing,
underscoring the need to identify and
develop effective treatments. As a result,
there has been a strong effort to create
animal models to help study these
diseases.
NIH inventors have created a new
mouse model for obesity and type II
diabetes. In this model, both copies of
the ANKRD26 gene are inactivated by
the insertion of a marker gene (betagalactosidase) into the open reading
frame of the gene. The resulting
knockout mouse exhibits extreme
obesity, increased organ and body size,
E:\FR\FM\25JAN1.SGM
25JAN1
4604
Federal Register / Vol. 73, No. 17 / Friday, January 25, 2008 / Notices
and acquired insulin resistance. The
mouse also expresses the marker gene,
thereby allowing the monitoring of
ANKRD26 expression patterns.
Applications:
Study and identify treatments for
obesity and type II diabetes.
Examine ANKRD26 expression under
various conditions.
Study the progression of obesity and
type II diabetes in a specific genetic
background.
Advantages:
Distinct phenotype from other mouse
models for obesity and type II diabetes
allows broader study of the diseases
when used in combination with other
mouse models.
Distinct phenotype allows the study
of obesity in a previously unidentified
genetic background.
Benefits: Obesity can increase the
susceptibility to other health conditions
such as cardiovascular disease. It has
been reported that billions of tax dollars
a year are spent in the treatment of
obesity-attributable conditions. The use
of this animal model could result in
social benefit, in terms of both health
and financial concerns, by leading to the
development of new methods of treating
obesity. Furthermore, the incidence of
obesity has more than doubled over the
past 10 years, suggesting that the
discovery of new treatments would
result in strong financial returns.
Inventor: Ira Pastan (NCI).
Publication: TK Bera et al. A model
for obesity and gigantism due to
disruption of the Ankrd26 gene. Proc
Natl Acad Sci USA. 2008 Jan
8;105(1):270–275.
Patent Status: HHS Reference No. E–
156–2007/0—Research Tool. Patent
protection is not being sought for this
technology.
Licensing Status: Available for
licensing.
Licensing Contact: David A.
Lambertson, PhD; 301–435–4632;
lambertsond@mail.nih.gov.
jlentini on PROD1PC65 with NOTICES
Photosensitization by Nuclear
Receptor-Ligand Complexes and Cell
Ablation Uses Thereof
Description of Invention: Androgen
receptors (AR) mediate the effects of
male steroid hormones and contribute to
a wide variety of physiological and
pathophysiological conditions. Prostate
cancer development and progression are
mediated through AR, a liganddependent transcription factor, and it is
present in all stages of prostate
carcinoma. Increased levels of PSA, an
AR-induced prostate tumor-specific
protein, are indicative of prostate
cancer. Benign, non-cancerous
VerDate Aug<31>2005
16:59 Jan 24, 2008
Jkt 214001
conditions are also AR-dependent and
can be therapeutic targets as well.
This technology is a method to cause
AR-induced cell death (apoptosis)
through photoactivation of a nonsteroidal androgen receptor antagonist
1,2,3,4-tetrahydro-2,2-dimethyl-6(trifluoromethyl)-8-pyridono[5,6-g]
quinoline (TDPQ). Upon TDPQ binding
to AR, a highly potent photocytoxic
reaction induced once the TDPQ-AR
complex is exposed to visible light
irradiation of a specific wavelength. The
inventors have cell-culture results
demonstrating that cell death is a
function of TDPQ, AR and light
irradiation. This treatment method can
potentially target AR-containing
cancerous cells, while sparing nearby
cells that lack AR.
The process has been extended to
other nuclear receptors by choice of
other photoactivatable ligands for these
receptors. Certain suitable ligands are
marketed drugs.
Applications: Therapeutic
compounds to treat AR related
conditions such as prostate cancer,
baldness, hirsutism, and acne.
Potential therapeutics for
progesterone and glucorticoid receptor
ligand related conditions such as breast
and brain cancers, lymphoma, leukemia
and arthritis.
Method to treat androgen,
progesterone, and glucorticoid receptor
related conditions.
Market: Prostate cancer is the second
most common type of cancer among
men, wherein one in six men will be
diagnosed with prostate cancer.
An estimated 218,890 new cases of
prostate cancer and 27,050 deaths due
to prostate cancer in the U.S. in 2007.
Hirsutism affects approximately 5%
of adult women in the United States.
Hair loss and acne industries are
worth several billions of dollars.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: William T. Schrader et al.
(NIEHS).
Publications:
1. B Risek et al. Androgen ReceptorMediated Apoptosis is Regulated by
Photoactivatable AR Ligands. Presented
at the Annual Meeting of the Endocrine
Society in Toronto, Canada in June
2007.
2. B Risek et al. Photocytotoxic
Properties of the Non-Steroidal
Androgen Receptor Antagonist TDPQ.
Presented at the Annual Meeting of the
Endocrine Society in Boston, MA in
June 2006.
Patent Status: U.S. Provisional
Application No. 60/926,218 filed 24 Apr
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
2007 (HHS Reference No. E–108–2007/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Antibodies and Polypeptides Specific to
AAMP–1: Diagnostic and Therapeutic
Uses Thereof
Description of Invention: Angioassociated migratory cell protein
(AAMP–1) was first isolated from a
human melanoma cell line as a motilityassociated cell protein. AAMP–1
contains two immunoglobin domains,
six WD40 repeats, and a heparinbinding domain. In vitro, over
expression of AAMP–1 promotes tumor
cell invasion and metastasis as well as
angiogenesis. AAMP–1 was later found
to be over expressed in endothelial
cells, cytotrophoblasts, and poorly
differentiated colon adenocarcinoma
cells found in lymphatics. In addition,
gene expression studies have shown
that AAMP–1 is over expressed in breast
and gastrointestinal tumors. The issued
patents claim proteins, polypeptides,
and recombinant polyclonal antibodies
specific to AAMP–1 and their use in
diagnostic and therapeutic applications.
Applications: The antibodies specific
to AAMP–1 can detect formalin-fixed
antigen and SDS-denatured antigen.
These antibodies can be used for
detailed expression studies of AAMP–1
in different cancer cell lines.
The antibodies could also be used to
detect AAMP–1 in patient’s sera as a
useful diagnostic marker for multiple
carcinomas including high nuclear
grade ductal carcinoma in situ (Clinical
Cancer Research Dec 2002 8:3788–95).
Claimed proteins and polypeptides
could also be used to promote cell
adhesion to a substrate, promote tissue
acceptance of prostheses, and promote
wound healing.
Development Status: This technology
is currently in the pre-clinical stage of
development.
Market: Estimated new cases and
deaths from breast cancer in the United
States in 2007: New cases: 178,480
(female); 2,030 (male); Deaths: 40,460
(female); 450 (male).
Inventors: Marie Beckner, Henry
Krutzsch and Lance Liotta (NCI).
Publications:
1. ME Beckner et al. AAMP, a newly
identified protein, shares a common
epitope with alpha-actinin and a fast
skeletal muscle fiber protein. Exp Cell
Res. 1996 Jun 15;225(2):306–314.
2. A Adeyinka et al. Analysis of gene
expression in ductal carcinoma in situ
of the breast. Clin Can Res. 2002
Dec;8(12):3788–3795.
E:\FR\FM\25JAN1.SGM
25JAN1
Federal Register / Vol. 73, No. 17 / Friday, January 25, 2008 / Notices
Patent Status: U.S. Patent No.
6,274,134 issued 14 Aug 2001 (HHS
Reference No. E–084–1991/1–US–01);
Australian Patent No. 684,806 issued 23
Apr 1998 (HHS Reference No. E–084–
1991/1–AU–05); Australian Patent No.
668,134 issued 26 Apr 1996 (HHS
Reference No. E–084–1991/0–AU–03)
and Japanese Patent No. 3,715,313
issued 9 November 2005 (HHS
Reference No. E–084–1991/1–JP–04).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Surekha Vathyam,
PhD; 301–435–4076;
vathyams@mail.nih.gov.
Dated: January 16, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–1244 Filed 1–24–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
jlentini on PROD1PC65 with NOTICES
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Human Papillomavirus microRNA
Diagnostics and Therapeutics
Description of Technology: Available
for licensing and commercial
development are patent rights that cover
the uses of a p53 specific microRNA
(miRNA). It has been reported that the
VerDate Aug<31>2005
16:59 Jan 24, 2008
Jkt 214001
tumor suppressive mRNA miR–34a is
downregulated in HPV-infected primary
keratinocytes. miR–34a arrests the cell
cycle at G2 phase and promotes
apoptosis. Therapeutic restoration of
normal miR–34a expression levels and/
or simultaneous stabilization of p53
(inhibited by HPV E6) may induce miR–
34a accumulation in G0/G1 phase and
potentially arrest tumor growth.
Applications: Cervical cancer; Human
papillomavirus; Therapeutics.
Inventors: Zhi-Ming Zheng, Xiaohong
Wang (NCI).
Relevant Publications:
1. WO Lui et al. Patterns of known
and novel small RNAs in human
cervical cancer. Cancer Res. 2007 Jul
1;67(13):6031–6043.
2. I Martinez et al. Human
papillomavirus type 16 reduces the
expression of microRNA–218 in cervical
carcinoma cells. Oncogene 2007 Nov 12;
Advance online publication,
doi:10.1038/sj.onc.1210919.
Patent Status: U.S. Provisional
Application No. 60/983,368 filed 29 Oct
2007 (HHS Reference No. E–029–2008/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Michael A.
Shmilovich, Esq.; 301/435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute HIV and
AIDS Malignancy Branch is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize HPV-induced aberrant
expression of microRNAs for cervical
cancer diagnostics and therapeutics.
Please contact John D. Hewes, PhD at
301–435–3121 or hewesj@mail.nih.gov
for more information.
Nitroxide Radical as a Treatment for
Neurodegeneration
Description of Technology: This
invention describes the use of a
nitroxide radical to treat or prevent the
progression of neurodegeneration
characterized by a deficiency in iron
regulatory protein 2 (IRP 2) function.
The inventors discovered that IRP 2 null
mice with adult-onset
neurodegeneration and microcytic
anemia regain activity of iron regulatory
protein 1 (IRP 1) after eating food
formulations containing specific
nitroxide radicals. The inventors also
discovered the nitroxide agent prevents
the progression of neurodegeneration by
attacking inhibitory iron-sulfur clusters
found on IRP 1 thereby allowing IRP 1
to bind to iron responsive elements
found on transcripts that encode iron
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
4605
metabolism proteins that regulate
cellular iron homeostasis in the brain.
Applications: Treatment for
neurological disorders resulting from a
deficiency in the amount of bioavailable
iron in the central nervous system,
including Alzheimer’s and Parkinson’s
disease, erythropoietic protoporphyria
or adult-onset neurodegeneration.
Market: Over 22 million people suffer
from neurodegenerative diseases
worldwide, and in 2050, this number
could triple due to increased life
expectancy and an increased aging
population.
Development Status: Early-stage.
Inventors: Tracey Rouault et al.
(NICHD).
Patent Status: U.S. Provisional
Application No. 60/894,134 filed 09 Mar
2007 (HHS Reference No. E–153–2007/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Charlene A.
Sydnor, PhD; 301/435–4689;
sydnorc@mail.nih.gov.
A Sensitive, High Throughput
Pseudovirus-Based Papillomavirus
Neutralization Assay for HPV 16 and
HPV 18
Description of Technology: This
invention is a research tool for
measuring protective antibody
responses against Human Papilloma
Viruses (HPV). Sensitive highthroughput neutralization assays, based
upon pseudoviruses carrying a secreted
alkaline phosphatase (SEAP) reporter
gene, were developed and validated by
the inventors for HPV 16, HPV 18, and
bovine papillomavirus 1 (BPV1). In a
96-well plate format, the assay was
reproducible and appears to be as
sensitive as, but more type-specific
than, a standard papillomavirus-like
particle (VLP)-based enzyme-linked
immunosorbent assay (ELISA). The
SEAP pseudovirus-based neutralization
assay should be a practical method for
quantifying potentially protective
antibody responses in HPV natural
history and prophylactic vaccine
studies.
Inventors: John T. Schiller (NCI),
Douglas R. Lowy (NCI), Christopher
Buck (NCI), Diana V. Pastrana (NCI), et
al.
Publication: The assay is further
described in Pastrana et al., ‘‘Reactivity
of human sera in a sensitive, highthroughput pseudovirus-based
papillomavirus neutralization assay for
HPV16 and HPV18,’’ Virology. 2004 Apr
10;321(2):205–216.
Patent Status: HHS Reference No. E–
137–2004/0—Research Material.
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 73, Number 17 (Friday, January 25, 2008)]
[Notices]
[Pages 4603-4605]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-1244]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Diagnosis and Treatment of Barrett's Esophagus and Associated
Esophageal Adenocarcinoma
Description of Invention: Barrett's esophagus is a condition in
which the normal esophageal tissue lining has been replaced by an
abnormal lining of gastric and intestinal tissue resulting from chronic
gastroesophageal reflux disease. Patients have an increased risk of
developing esophageal adenocarcinoma, which is often detected at later
stages and is associated with poor prognosis. Survival rates are very
low ranging from 10% in Europe to 16% in the United States.
Available for licensing are microRNA (miRNA) biomarkers that show
differential expression in the adenocarcinoma diagnosis and Barrett's
esophagus status, and they can predict diagnosis and Barrett's
esophagus with accuracies of 71.4% and 74.7%, respectively. Thus, these
miRNA biomarkers that may predispose individuals to Barrett's esophagus
and/or esophageal adenocarcinoma could provide a means for earlier
detection and help in better identifying treatment options.
Applications:
Method to diagnose and treat Barrett's esophagus and esophageal
adenocarcinoma.
miRNA pharmaceutical compositions to treat Barrett's esophagus.
Advantages: Early diagnostic that can more accurately stratify
patients for increased survival rates and appropriate treatments.
Development Status: The technology is currently in the pre-clinical
stage of development.
Market: Esophageal cancer is the 8th most common cancer and 6th
most common cause of cancer worldwide.
Survival rate of esophageal cancer is 10% to 16% in Europe and
United States respectively.
miRNA technologies have an emerging market, and in 2007, it was
worth an estimated 23 million dollars in the U.S. and it has a
projected annual growth rate of 100%.
Inventors: Ewy Mathe (NCI), Curtis C. Harris (NCI), et al.
Patent Status: U.S. Provisional Application No. 60/979,300 filed 11
Oct 2007 (HHS Reference No. E-008-2008/0-US-01).
Licensing Status: Available for non-exclusive licensing.
Licensing Contact: Jennifer Wong; 301-435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The Laboratory of Human
Carcinogenesis at the National Cancer Institute is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize methods to
diagnose and treat Barrett's esophagus and esophageal carcinoma. Please
contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for
more information.
Mouse Model for Obesity and Type 2 Diabetes Due to Inactivation of
ANKRD26 Gene
Description of Invention: Obesity and type II diabetes are major
health hazards both in the United States and internationally. The
incidence of obesity has been steadily increasing, underscoring the
need to identify and develop effective treatments. As a result, there
has been a strong effort to create animal models to help study these
diseases.
NIH inventors have created a new mouse model for obesity and type
II diabetes. In this model, both copies of the ANKRD26 gene are
inactivated by the insertion of a marker gene (beta-galactosidase) into
the open reading frame of the gene. The resulting knockout mouse
exhibits extreme obesity, increased organ and body size,
[[Page 4604]]
and acquired insulin resistance. The mouse also expresses the marker
gene, thereby allowing the monitoring of ANKRD26 expression patterns.
Applications:
Study and identify treatments for obesity and type II diabetes.
Examine ANKRD26 expression under various conditions.
Study the progression of obesity and type II diabetes in a specific
genetic background.
Advantages:
Distinct phenotype from other mouse models for obesity and type II
diabetes allows broader study of the diseases when used in combination
with other mouse models.
Distinct phenotype allows the study of obesity in a previously
unidentified genetic background.
Benefits: Obesity can increase the susceptibility to other health
conditions such as cardiovascular disease. It has been reported that
billions of tax dollars a year are spent in the treatment of obesity-
attributable conditions. The use of this animal model could result in
social benefit, in terms of both health and financial concerns, by
leading to the development of new methods of treating obesity.
Furthermore, the incidence of obesity has more than doubled over the
past 10 years, suggesting that the discovery of new treatments would
result in strong financial returns.
Inventor: Ira Pastan (NCI).
Publication: TK Bera et al. A model for obesity and gigantism due
to disruption of the Ankrd26 gene. Proc Natl Acad Sci USA. 2008 Jan
8;105(1):270-275.
Patent Status: HHS Reference No. E-156-2007/0--Research Tool.
Patent protection is not being sought for this technology.
Licensing Status: Available for licensing.
Licensing Contact: David A. Lambertson, PhD; 301-435-4632;
lambertsond@mail.nih.gov.
Photosensitization by Nuclear Receptor-Ligand Complexes and Cell
Ablation Uses Thereof
Description of Invention: Androgen receptors (AR) mediate the
effects of male steroid hormones and contribute to a wide variety of
physiological and pathophysiological conditions. Prostate cancer
development and progression are mediated through AR, a ligand-dependent
transcription factor, and it is present in all stages of prostate
carcinoma. Increased levels of PSA, an AR-induced prostate tumor-
specific protein, are indicative of prostate cancer. Benign, non-
cancerous conditions are also AR-dependent and can be therapeutic
targets as well.
This technology is a method to cause AR-induced cell death
(apoptosis) through photoactivation of a non-steroidal androgen
receptor antagonist 1,2,3,4-tetrahydro-2,2-dimethyl-6-
(trifluoromethyl)-8-pyridono[5,6-g] quinoline (TDPQ). Upon TDPQ binding
to AR, a highly potent photocytoxic reaction induced once the TDPQ-AR
complex is exposed to visible light irradiation of a specific
wavelength. The inventors have cell-culture results demonstrating that
cell death is a function of TDPQ, AR and light irradiation. This
treatment method can potentially target AR-containing cancerous cells,
while sparing nearby cells that lack AR.
The process has been extended to other nuclear receptors by choice
of other photoactivatable ligands for these receptors. Certain suitable
ligands are marketed drugs.
Applications: Therapeutic compounds to treat AR related conditions
such as prostate cancer, baldness, hirsutism, and acne.
Potential therapeutics for progesterone and glucorticoid receptor
ligand related conditions such as breast and brain cancers, lymphoma,
leukemia and arthritis.
Method to treat androgen, progesterone, and glucorticoid receptor
related conditions.
Market: Prostate cancer is the second most common type of cancer
among men, wherein one in six men will be diagnosed with prostate
cancer.
An estimated 218,890 new cases of prostate cancer and 27,050 deaths
due to prostate cancer in the U.S. in 2007.
Hirsutism affects approximately 5% of adult women in the United
States.
Hair loss and acne industries are worth several billions of
dollars.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: William T. Schrader et al. (NIEHS).
Publications:
1. B Risek et al. Androgen Receptor-Mediated Apoptosis is Regulated
by Photoactivatable AR Ligands. Presented at the Annual Meeting of the
Endocrine Society in Toronto, Canada in June 2007.
2. B Risek et al. Photocytotoxic Properties of the Non-Steroidal
Androgen Receptor Antagonist TDPQ. Presented at the Annual Meeting of
the Endocrine Society in Boston, MA in June 2006.
Patent Status: U.S. Provisional Application No. 60/926,218 filed 24
Apr 2007 (HHS Reference No. E-108-2007/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301-435-4633;
wongje@mail.nih.gov.
Antibodies and Polypeptides Specific to AAMP-1: Diagnostic and
Therapeutic Uses Thereof
Description of Invention: Angio-associated migratory cell protein
(AAMP-1) was first isolated from a human melanoma cell line as a
motility-associated cell protein. AAMP-1 contains two immunoglobin
domains, six WD40 repeats, and a heparin-binding domain. In vitro, over
expression of AAMP-1 promotes tumor cell invasion and metastasis as
well as angiogenesis. AAMP-1 was later found to be over expressed in
endothelial cells, cytotrophoblasts, and poorly differentiated colon
adenocarcinoma cells found in lymphatics. In addition, gene expression
studies have shown that AAMP-1 is over expressed in breast and
gastrointestinal tumors. The issued patents claim proteins,
polypeptides, and recombinant polyclonal antibodies specific to AAMP-1
and their use in diagnostic and therapeutic applications.
Applications: The antibodies specific to AAMP-1 can detect
formalin-fixed antigen and SDS-denatured antigen. These antibodies can
be used for detailed expression studies of AAMP-1 in different cancer
cell lines.
The antibodies could also be used to detect AAMP-1 in patient's
sera as a useful diagnostic marker for multiple carcinomas including
high nuclear grade ductal carcinoma in situ (Clinical Cancer Research
Dec 2002 8:3788-95).
Claimed proteins and polypeptides could also be used to promote
cell adhesion to a substrate, promote tissue acceptance of prostheses,
and promote wound healing.
Development Status: This technology is currently in the pre-
clinical stage of development.
Market: Estimated new cases and deaths from breast cancer in the
United States in 2007: New cases: 178,480 (female); 2,030 (male);
Deaths: 40,460 (female); 450 (male).
Inventors: Marie Beckner, Henry Krutzsch and Lance Liotta (NCI).
Publications:
1. ME Beckner et al. AAMP, a newly identified protein, shares a
common epitope with alpha-actinin and a fast skeletal muscle fiber
protein. Exp Cell Res. 1996 Jun 15;225(2):306-314.
2. A Adeyinka et al. Analysis of gene expression in ductal
carcinoma in situ of the breast. Clin Can Res. 2002 Dec;8(12):3788-
3795.
[[Page 4605]]
Patent Status: U.S. Patent No. 6,274,134 issued 14 Aug 2001 (HHS
Reference No. E-084-1991/1-US-01); Australian Patent No. 684,806 issued
23 Apr 1998 (HHS Reference No. E-084-1991/1-AU-05); Australian Patent
No. 668,134 issued 26 Apr 1996 (HHS Reference No. E-084-1991/0-AU-03)
and Japanese Patent No. 3,715,313 issued 9 November 2005 (HHS Reference
No. E-084-1991/1-JP-04).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Surekha Vathyam, PhD; 301-435-4076;
vathyams@mail.nih.gov.
Dated: January 16, 2008.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-1244 Filed 1-24-08; 8:45 am]
BILLING CODE 4140-01-P
